Literature DB >> 23399726

Prostate cancer: Interpreting cost-utility analysis of prostate cancer treatment.

James B Yu1.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23399726     DOI： 10.1038/nrurol.2013.17

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  9 in total

1.  Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer.

Authors:  Andre Konski; Deborah Watkins-Bruner; Steven Feigenberg; Alexandra Hanlon; Sachin Kulkarni; J Robert Beck; Eric M Horwitz; Alan Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-08-02       Impact factor: 7.038

2.  Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation.

Authors:  Felix K-H Chun; Alberto Briganti; Shahrokh F Shariat; Markus Graefen; Francesco Montorsi; Andreas Erbersdobler; Thomas Steuber; Andrea Salonia; Eike Currlin; Vincenzo Scattoni; Martin G Friedrich; Thorsten Schlomm; Alexander Haese; Uwe Michl; Renzo Colombo; Hans Heinzer; Luc Valiquette; Patrizio Rigatti; Claus G Roehrborn; Hartwig Huland; Pierre I Karakiewicz
Journal:  BJU Int       Date:  2006-08       Impact factor: 5.588

3.  The learning curve for reducing complications of robotic-assisted laparoscopic radical prostatectomy by a single surgeon.

Authors:  Yen-Chuan Ou; Chi-Rei Yang; John Wang; Chun-Kuang Yang; Chen-Li Cheng; Vipul R Patel; Ashutosh K Tewari
Journal:  BJU Int       Date:  2010-11-02       Impact factor: 5.588

4.  Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis.

Authors:  Matthew R Cooperberg; Naren R Ramakrishna; Steven B Duff; Kathleen E Hughes; Sara Sadownik; Joseph A Smith; Ashutosh K Tewari
Journal:  BJU Int       Date:  2012-12-28       Impact factor: 5.588

5.  Factors associated with treatment received by men diagnosed with prostate cancer in Queensland, Australia.

Authors:  Peter D Baade; Danny R Youlden; Robert A Gardiner; Megan Ferguson; Joanne F Aitken; John Yaxley; Suzanne K Chambers
Journal:  BJU Int       Date:  2012-09-27       Impact factor: 5.588

6.  Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix.

Authors:  Michael J Zelefsky; James A Eastham; Angel M Cronin; Zvi Fuks; Zhigang Zhang; Yoshiya Yamada; Andrew Vickers; Peter T Scardino
Journal:  J Clin Oncol       Date:  2010-02-16       Impact factor: 44.544

7.  Cost implications of the rapid adoption of newer technologies for treating prostate cancer.

Authors:  Paul L Nguyen; Xiangmei Gu; Stuart R Lipsitz; Toni K Choueiri; Wesley W Choi; Yin Lei; Karen E Hoffman; Jim C Hu
Journal:  J Clin Oncol       Date:  2011-03-14       Impact factor: 44.544

8.  Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy.

Authors:  Ofer Yossepowitch; Scott E Eggener; Angel M Serio; Brett S Carver; Fernando J Bianco; Peter T Scardino; James A Eastham
Journal:  Eur Urol       Date:  2007-10-12       Impact factor: 20.096

9.  Five reasons that many comparative effectiveness studies fail to change patient care and clinical practice.

Authors:  Justin W Timbie; D Steven Fox; Kristin Van Busum; Eric C Schneider
Journal:  Health Aff (Millwood)       Date:  2012-10       Impact factor: 6.301
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.